Paolo Antonio S. Silva, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 73 | 2023 | 1299 | 14.580 |
Why?
|
Macular Edema | 26 | 2023 | 387 | 7.500 |
Why?
|
Photography | 19 | 2023 | 537 | 4.360 |
Why?
|
Retinal Vessels | 16 | 2023 | 864 | 2.730 |
Why?
|
Diabetes Mellitus | 14 | 2023 | 5887 | 2.360 |
Why?
|
Retina | 18 | 2023 | 2663 | 2.330 |
Why?
|
Fluorescein Angiography | 15 | 2023 | 1086 | 2.240 |
Why?
|
Diagnostic Techniques, Ophthalmological | 9 | 2019 | 252 | 1.940 |
Why?
|
Telemedicine | 16 | 2022 | 3104 | 1.880 |
Why?
|
Telepathology | 3 | 2016 | 77 | 1.500 |
Why?
|
Mydriatics | 5 | 2023 | 67 | 1.440 |
Why?
|
Laser Coagulation | 9 | 2017 | 333 | 1.250 |
Why?
|
Retinal Diseases | 6 | 2023 | 711 | 1.180 |
Why?
|
Angiogenesis Inhibitors | 11 | 2018 | 2062 | 1.100 |
Why?
|
Ophthalmoscopy | 6 | 2018 | 172 | 1.090 |
Why?
|
Ophthalmology | 3 | 2022 | 560 | 1.050 |
Why?
|
Visual Acuity | 15 | 2020 | 2714 | 1.040 |
Why?
|
Mydriasis | 2 | 2023 | 14 | 1.020 |
Why?
|
Triamcinolone Acetonide | 5 | 2013 | 105 | 1.010 |
Why?
|
Retinal Neovascularization | 5 | 2015 | 288 | 0.980 |
Why?
|
Vitrectomy | 9 | 2017 | 392 | 0.950 |
Why?
|
Tomography, Optical Coherence | 13 | 2023 | 2958 | 0.830 |
Why?
|
Diagnostic Imaging | 8 | 2021 | 3543 | 0.720 |
Why?
|
Retinal Hemorrhage | 3 | 2020 | 98 | 0.690 |
Why?
|
Vitreous Body | 5 | 2013 | 400 | 0.620 |
Why?
|
Pupil | 3 | 2016 | 146 | 0.620 |
Why?
|
Diabetes Mellitus, Type 1 | 11 | 2019 | 3440 | 0.600 |
Why?
|
Kallikrein-Kinin System | 2 | 2016 | 9 | 0.560 |
Why?
|
Eye | 3 | 2023 | 715 | 0.540 |
Why?
|
Vitreous Hemorrhage | 2 | 2015 | 47 | 0.540 |
Why?
|
Glucocorticoids | 4 | 2013 | 2170 | 0.500 |
Why?
|
Intravitreal Injections | 8 | 2018 | 401 | 0.500 |
Why?
|
Artificial Intelligence | 4 | 2023 | 2659 | 0.460 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2016 | 712 | 0.450 |
Why?
|
Cataract Extraction | 2 | 2017 | 465 | 0.450 |
Why?
|
Retinal Vein Occlusion | 2 | 2014 | 149 | 0.430 |
Why?
|
Hemangioblastoma | 1 | 2013 | 62 | 0.430 |
Why?
|
Fundus Oculi | 7 | 2020 | 560 | 0.420 |
Why?
|
Phacoemulsification | 1 | 2014 | 151 | 0.410 |
Why?
|
Diabetes Complications | 3 | 2014 | 1322 | 0.410 |
Why?
|
Lens Implantation, Intraocular | 1 | 2014 | 192 | 0.410 |
Why?
|
Automation | 1 | 2015 | 588 | 0.400 |
Why?
|
Severity of Illness Index | 14 | 2023 | 15965 | 0.400 |
Why?
|
Hyperlipidemias | 1 | 2017 | 773 | 0.400 |
Why?
|
von Hippel-Lindau Disease | 1 | 2013 | 154 | 0.400 |
Why?
|
Cataract | 2 | 2017 | 837 | 0.400 |
Why?
|
Physical Examination | 2 | 2015 | 1262 | 0.390 |
Why?
|
Retinal Neoplasms | 1 | 2013 | 151 | 0.380 |
Why?
|
Mass Screening | 3 | 2016 | 5455 | 0.370 |
Why?
|
Humans | 84 | 2023 | 768451 | 0.360 |
Why?
|
Sodium Chloride | 1 | 2013 | 585 | 0.360 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2016 | 3520 | 0.350 |
Why?
|
Diabetes Mellitus, Type 2 | 12 | 2019 | 12242 | 0.340 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2015 | 9066 | 0.300 |
Why?
|
Polypharmacy | 1 | 2010 | 307 | 0.290 |
Why?
|
Disease Progression | 9 | 2020 | 13655 | 0.290 |
Why?
|
Vitreoretinal Surgery | 2 | 2017 | 28 | 0.270 |
Why?
|
Prospective Studies | 12 | 2023 | 54914 | 0.260 |
Why?
|
Retrospective Studies | 20 | 2023 | 81834 | 0.260 |
Why?
|
Middle Aged | 36 | 2023 | 223418 | 0.260 |
Why?
|
Intraocular Pressure | 3 | 2015 | 1304 | 0.250 |
Why?
|
Male | 39 | 2023 | 364781 | 0.240 |
Why?
|
Female | 39 | 2023 | 396943 | 0.230 |
Why?
|
Steroids | 1 | 2009 | 937 | 0.220 |
Why?
|
Sensitivity and Specificity | 6 | 2023 | 14728 | 0.220 |
Why?
|
Ocular Hypertension | 1 | 2015 | 211 | 0.220 |
Why?
|
Aged | 26 | 2023 | 171520 | 0.210 |
Why?
|
Cross-Sectional Studies | 10 | 2023 | 26351 | 0.210 |
Why?
|
Fluoresceins | 1 | 2023 | 236 | 0.210 |
Why?
|
Vision Disorders | 3 | 2014 | 1092 | 0.200 |
Why?
|
Color | 1 | 2023 | 297 | 0.190 |
Why?
|
United States Indian Health Service | 1 | 2021 | 31 | 0.190 |
Why?
|
Blood-Retinal Barrier | 1 | 2021 | 63 | 0.180 |
Why?
|
Evidence-Based Medicine | 3 | 2017 | 3708 | 0.180 |
Why?
|
Adult | 25 | 2023 | 223542 | 0.170 |
Why?
|
Antihypertensive Agents | 2 | 2015 | 2028 | 0.170 |
Why?
|
Eyelids | 1 | 2022 | 280 | 0.170 |
Why?
|
Uveitis | 1 | 2023 | 398 | 0.160 |
Why?
|
Optics and Photonics | 2 | 2018 | 307 | 0.160 |
Why?
|
Choroid | 1 | 2020 | 363 | 0.150 |
Why?
|
Glaucoma, Neovascular | 2 | 2015 | 37 | 0.150 |
Why?
|
Cohort Studies | 5 | 2023 | 41797 | 0.150 |
Why?
|
Aged, 80 and over | 10 | 2015 | 59680 | 0.140 |
Why?
|
Injections | 2 | 2010 | 840 | 0.130 |
Why?
|
Disease Management | 2 | 2017 | 2533 | 0.130 |
Why?
|
Retreatment | 2 | 2015 | 601 | 0.130 |
Why?
|
Plasma Kallikrein | 1 | 2016 | 21 | 0.130 |
Why?
|
Vision, Low | 1 | 2017 | 163 | 0.130 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39430 | 0.130 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2016 | 184 | 0.120 |
Why?
|
Pseudophakia | 1 | 2014 | 61 | 0.120 |
Why?
|
Ciliary Body | 1 | 2015 | 168 | 0.120 |
Why?
|
Glaucoma Drainage Implants | 1 | 2015 | 107 | 0.110 |
Why?
|
Tropicamide | 1 | 2013 | 22 | 0.110 |
Why?
|
Computer Systems | 1 | 2015 | 470 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9263 | 0.110 |
Why?
|
Signal Processing, Computer-Assisted | 3 | 2012 | 1496 | 0.100 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2013 | 193 | 0.100 |
Why?
|
Phenylephrine | 1 | 2013 | 294 | 0.100 |
Why?
|
Young Adult | 8 | 2018 | 60045 | 0.100 |
Why?
|
Biological Availability | 2 | 2012 | 390 | 0.100 |
Why?
|
Capillary Permeability | 1 | 2016 | 773 | 0.100 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 305 | 0.100 |
Why?
|
Reproducibility of Results | 6 | 2020 | 20231 | 0.100 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 665 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2023 | 1876 | 0.090 |
Why?
|
Retinal Detachment | 1 | 2015 | 429 | 0.090 |
Why?
|
Eye Proteins | 1 | 2013 | 633 | 0.080 |
Why?
|
Double-Blind Method | 3 | 2015 | 12450 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2012 | 1543 | 0.080 |
Why?
|
ROC Curve | 1 | 2017 | 3624 | 0.080 |
Why?
|
Choroidal Neovascularization | 1 | 2012 | 364 | 0.080 |
Why?
|
Ubiquitin | 1 | 2013 | 843 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2013 | 8559 | 0.070 |
Why?
|
Specialization | 1 | 2012 | 782 | 0.070 |
Why?
|
Glaucoma, Open-Angle | 1 | 2014 | 742 | 0.070 |
Why?
|
Drug Combinations | 1 | 2013 | 2079 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 5532 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3735 | 0.070 |
Why?
|
Risk Factors | 5 | 2015 | 74915 | 0.070 |
Why?
|
Point-of-Care Systems | 1 | 2015 | 1228 | 0.070 |
Why?
|
Glaucoma | 1 | 2016 | 1193 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2022 | 22293 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2022 | 14766 | 0.060 |
Why?
|
Orbit | 1 | 2009 | 459 | 0.060 |
Why?
|
Adolescent | 4 | 2015 | 89168 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15880 | 0.060 |
Why?
|
Tonometry, Ocular | 1 | 2015 | 238 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2742 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3484 | 0.060 |
Why?
|
Aptamers, Nucleotide | 2 | 2016 | 166 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1518 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2021 | 4877 | 0.050 |
Why?
|
Uvea | 1 | 2023 | 31 | 0.050 |
Why?
|
Proteome | 1 | 2013 | 1881 | 0.050 |
Why?
|
Age of Onset | 1 | 2010 | 3342 | 0.050 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3408 | 0.050 |
Why?
|
Recurrence | 1 | 2013 | 8510 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7451 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2009 | 1891 | 0.040 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5367 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5510 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2013 | 65409 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2010 | 3111 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2013 | 16029 | 0.030 |
Why?
|
Canada | 1 | 2022 | 2143 | 0.030 |
Why?
|
Blood Glucose | 1 | 2010 | 6429 | 0.030 |
Why?
|
Filtering Surgery | 1 | 2015 | 33 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2017 | 15880 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 40271 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 134 | 0.030 |
Why?
|
Carbonic Anhydrase I | 1 | 2013 | 4 | 0.030 |
Why?
|
Algorithms | 2 | 2016 | 14158 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9505 | 0.030 |
Why?
|
Aldehyde Reductase | 1 | 2013 | 70 | 0.030 |
Why?
|
United States | 1 | 2021 | 73121 | 0.030 |
Why?
|
Ophthalmic Solutions | 1 | 2014 | 315 | 0.030 |
Why?
|
Ophthalmoscopes | 1 | 2012 | 21 | 0.030 |
Why?
|
Tenon Capsule | 1 | 2012 | 6 | 0.030 |
Why?
|
Injections, Intraocular | 1 | 2012 | 36 | 0.020 |
Why?
|
Depth Perception | 1 | 2012 | 95 | 0.020 |
Why?
|
Artifacts | 1 | 2020 | 1927 | 0.020 |
Why?
|
Lysophospholipids | 1 | 2013 | 338 | 0.020 |
Why?
|
Animals | 3 | 2021 | 169418 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8730 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 30243 | 0.020 |
Why?
|
Cattle | 1 | 2013 | 3830 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1415 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2179 | 0.020 |
Why?
|
Observer Variation | 1 | 2012 | 2622 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2013 | 2150 | 0.020 |
Why?
|
Macular Degeneration | 1 | 2012 | 1016 | 0.010 |
Why?
|
Collagen | 1 | 2013 | 2646 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2204 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2012 | 1836 | 0.010 |
Why?
|
Neurons | 1 | 2021 | 9504 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2013 | 3586 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2012 | 3590 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6278 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23638 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9361 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 22365 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 18048 | 0.010 |
Why?
|
Mice | 1 | 2013 | 82045 | 0.000 |
Why?
|